Biochemist Joanne Lemieux worked with three other U of A researchers on a new study showing that a drug that cures deadly peritonitis in cats also works well enough against the coronavirus that causes COVID-19 to fast-track it into human clinical trials. (Photo: Supplied)
Fast-tracked research leads to phase 1 clinical trials.
Researchers at the University of Alberta are preparing to launch clinical trials of a drug used to cure a deadly disease caused by a coronavirus in cats that they expect will also be effective as a treatment for humans against COVID-19.
“In just two months, our results have shown that the drug is effective at inhibiting viral replication in cells with SARS-CoV-2,” said Joanne Lemieux, a professor of biochemistry in the Faculty of Medicine & Dentistry.
“This drug is very likely to work in humans, so we’re encouraged that it will be an effective antiviral treatment for COVID-19 patients.”
The drug is a protease inhibitor that interferes with the virus’s ability to replicate, thus ending an infection. Proteases are key to many body functions and are common targets for drugs to treat everything from high blood pressure to cancer and HIV.
First studied by U of A chemist John Vederas and biochemist Michael James following the 2003 outbreak of severe acute respiratory syndrome (SARS), the protease inhibitor was further developed by veterinary researchers who showed it cures a disease that is fatal in cats.
The work to test the drug against the coronavirus that causes COVID-19 was a co-operative effort between four U of A laboratories, run by Lemieux, Vederas, biochemistry professor Howard Young and the founding director of the Li Ka Shing Institute of Virology, Lorne Tyrrell. Some of the experiments were carried out by the Stanford Synchrotron Radiation Lightsource Structural Molecular Biology program.
Their findings were published today in the peer-reviewed journal Nature Communications after first being posted on BioRxIV, a research website.
“There’s a rule with COVID research that all results need to be made public immediately,” Lemieux said, which is why they were posted before being peer-reviewed.
She said interest in the work is high, with the paper being accessed thousands of times as soon as it was posted.
Lemieux explained that Vederas synthesized the compounds, and Tyrrell tested them against the SARS-CoV-2 virus in test tubes and in human cell lines. The Young and Lemieux groups then revealed the crystal structure of the drug as it binds with the protein.
”We determined the three-dimensional shape of the protease with the drug in the active site pocket, showing the mechanism of inhibition,” she said. “This will allow us to develop even more effective drugs.”
Lemieux said she will continue to test modifications of the inhibitor to make it an even better fit inside the virus.
But she said the current drug shows enough antiviral action against SARS-CoV-2 to proceed immediately to clinical trials.
“Typically for a drug to go into clinical trials, it has to be confirmed in the lab and then tested in animal models,” Lemieux said. “Because this drug has already been used to treat cats with coronavirus, and it’s effective with little to no toxicity, it’s already passed those stages and this allows us to move forward.”
“Because of the strong data that we and others have gathered we’re pursuing clinical trials for this drug as an antiviral for COVID-19.”
The researchers have established a collaboration with Anivive Life Sciences, a veterinary medicine company that is developing the drug for cats, to produce the quality and quantity of drug needed for human clinical trials. Lemieux said it will likely be tested in Alberta in combination with other promising antivirals such as remdesivir, the first treatment approved for conditional use in some countries including the United States and Canada.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
SARS-CoV-2 antiviral
- SARS-CoV-2 articles from across Nature Portfolio
Following antiviral treatment, SARS-CoV-2 (BA.5) showed dynamic genetic diversity with remdesivir resistant mutations leading to enhanced fusogenicity. Immunization via the respiratory route is ...
- High-risk patients with COVID symptoms should use PCR rather than rapid tests, study suggests
Study findings that reveal a sensitivity of 47% for COVID-19 rapid antigen tests (RATs) compared with reverse-transcription polymerase chain reaction (RT-PCR) tests during Omicron variant predominance ...
- Jun-12682, a SARS-CoV-2 PLpro inhibitor with potent antiviral activity in mice
Researchers from State University of New Jersey (Rutgers) and Oklahoma State University have published preclinical data for a novel a SARS-CoV-2 papain-like protease (PLpro) inhibitor being developed ...
- Identifying efficacious SARS-CoV-2 antivirals in a changing immune landscape
With almost 775 million COVID-19 cases reported worldwide and 67% of the global population vaccinated with a complete primary series of a COVID-19 vaccine, the deadly pace of the pandemic has slowed ...
- Study reveals how SARS-CoV-2 hijacks lung cells to drive COVID-19 severity
Prominent targets were lung-resident macrophages, of which one SARS-CoV-2 takes over transcriptomes, inducing a targeted host interferon (IFN) antiviral program, and several chemokines and pro ...
Go deeper with Google Headlines on:
SARS-CoV-2 antiviral
[google_news title=”” keyword=”SARS-CoV-2 antiviral” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
COVID-19 cure
- Covishield Controversy: AstraZeneca's Disclosure Reopens Pandora's Box Of Disputes
The COVID-19 vaccination drive in India has been embroiled in yet another controversy after AstraZeneca's recent admission regarding a rare side effect of its Covishield vaccine, reigniting political ...
- Peter Marks
When COVID-19 vaccines were developed that relied on a new technology ... single chemical to cell-based strategies like gene therapy that have the potential to cure disorders rather than simply treat ...
- Akiko Iwasaki
If nasal vaccines help fewer people get infected by the virus that causes COVID-19, she says, fewer people will develop Long COVID. That’s important, since there’s no known cure for the chronic ...
- Covishield cure comes with serious side effects
Sparking criticism and raising concerns, British-Swedish multinational pharmaceutical firm AstraZeneca has for the first time acknowledged in court documents in the UK that its Covid-19 vaccine, which ...
- Column: School nurses could be the cure to chronic absenteeism
Investing in school nurses guarantees that all children have the health support they need to learn, Williamsburg school nurse Megan Drakes writes in a guest column.
Go deeper with Google Headlines on:
COVID-19 cure
[google_news title=”” keyword=”COVID-19 cure” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]